2.77 0.00 (0.00%)
After hours: 5:36PM EDT
|Bid||2.77 x 34100|
|Ask||2.81 x 1000|
|Day's Range||2.75 - 2.89|
|52 Week Range||2.15 - 3.55|
|PE Ratio (TTM)||3.90|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The Incline Village, Nevada-based company said it had net income of 1 cent per share. Earnings, adjusted for one-time gains and costs, were 8 cents per share. The biotechnology company posted revenue of ...
Do you think penny stocks are best left to amateur traders who don’t understand that cheap stocks are cheap for a reason? It’s a misnomer, however, to think all penny stocks — let’s quantify them as equities priced at less than $5 per share — aren’t worth owning. Thanks to factors ranging from prolonged weakness in the commodities market to strategic stock splits to poorly-timed IPOs, a handful of these low-priced equities are actually compelling prospects.
Companies, such as Triple-S Management, are deemed to be undervalued because their shares are currently trading below their true values. Investors can benefit from buying these companies while they areRead More...
PDL BioPharma (PDLI) is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.
The Incline Village, Nevada-based company said it had net income of 15 cents per share. Earnings, adjusted for one-time gains and costs, were 17 cents per share. The biotechnology company posted revenue ...
PDL BioPharma Inc’s (NASDAQ:PDLI) most recent return on equity was a substandard 9.49% relative to its industry performance of 17.87% over the past year. Though PDLI’s recent performance is underwhelming,Read More...
There were some huge moves in the biotech space in the past week, with Portola Pharmaceuticals Inc (NASDAQ: PTLA ) slumping over 25 percent on perceived FDA risk after the company said the FDA may mandate ...
PDL BioPharma Inc (NASDAQ:PDLI) trades with a trailing P/E of 5x, which is lower than the industry average of 28.5x. Although some investors may jump to the conclusion that thisRead More...
You'll probably be surprised by some of the stock picks from a leading artificial-intelligence system.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to PDL BioPharma, Inc. Here are 5 ETFs with the largest exposure to PDLI-US. Comparing the performance and risk of PDL BioPharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Categories: Yahoo FinanceGet free summary analysis PDL BioPharma, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of PDL BioPharma, Inc. – Compugen Ltd., Nektar Therapeutics, BioTime, Inc., Mylan N.V., Amgen Inc., Eli Lilly and Company and Sangamo Therapeutics, Inc. (CGEN-US, NKTR-US, BTX-US, MYL-US, AMGN-US, LLY-US ... Read more (Read more...)
AstraZeneca (AZN) received CHMP recommendation for marketing approval of its pipeline candidate, benralizumab for treating severe eosinophilic asthma.